Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Jonathan Beall, Jordan Elm, James Chamberlain, Eric Rosenthal, Jaideep Kapur & Valerie Durkalski-Mauldin. (2023) An Expected Score Approach to Ordinal Outcomes in a Bayesian, Response Adaptive, Randomized Trial. Statistics in Biopharmaceutical Research 15:4, pages 820-825.
Read now
Read now
H. M. James Hung & John Lawrence. (2023) Composite Endpoints in Cardio-Renal Clinical Outcome Trials. Statistics in Biopharmaceutical Research 15:2, pages 318-322.
Read now
Read now
Ying Lu, Qian Zhao, Jiying Zou, Shiyan Yan, John S. Tamaresis, Lorene Nelson, Xin M. Tu, Jie Chen & Lu Tian. (2022) A Composite Endpoint for Treatment Benefit According to Patient Preference. Statistics in Biopharmaceutical Research 14:4, pages 408-422.
Read now
Read now
Scott R. Evans. (2022) Our Most Important Discovery: The Question. Statistics in Biopharmaceutical Research 14:4, pages 398-407.
Read now
Read now
Scott R. Evans. (2022) Radical Thinking: Scientific Rigor and Pragmatism. Statistics in Biopharmaceutical Research 14:2, pages 140-152.
Read now
Read now
Xiaoyan Yin, Toshimitsu Hamasaki & Scott R. Evans. (2021) Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART COMPASS): Design Considerations. Statistics in Biopharmaceutical Research 13:2, pages 181-191.
Read now
Read now
Scott R. Evans. (2021) Waking up to p: Comment on “The Role of p-Values in Judging the Strength of Evidence and Realistic Replication Expectations”. Statistics in Biopharmaceutical Research 13:1, pages 19-21.
Read now
Read now
Teresa A Simon, Marlene S Khouri, Tzuyung D Kou & Andres Gomez-Caminero. (2020) Realizing the Potential of the Patient Perspective. Patient Preference and Adherence 14, pages 2001-2007.
Read now
Read now
Ziqiao Wang & Jie Chen. (2020) Testing for Trend in Benefit-Risk Analysis with Prioritized Multiple Outcomes. Statistics in Biopharmaceutical Research 12:3, pages 380-389.
Read now
Read now
Matteo Bassetti, Daniele Roberto Giacobbe, Maddalena Peghin & Paurus Irani. (2019) A look at clinical trial design for new antimicrobials for the adult population. Expert Review of Clinical Pharmacology 12:11, pages 1037-1046.
Read now
Read now
Articles from other publishers (71)
Sandra M. Shi, Natalia Gouskova, Chan Mi Park, Thomas G. Travison, Lee-Jen Wei & Dae Hyun Kim. (2023) Balancing Benefit and Harm of Intensive Blood Pressure Lowering Based on Individual Outcome Profile Analysis. The American Journal of Medicine 136:12, pages 1196-1202.e2.
Crossref
Crossref
Lucy Vivash, Hannah Johns, Terence J. O'Brien & Leonid Churilov. (2023) The adaptation of the desirability of outcome ranking for interventional clinical trials in epilepsy: A novel consumer‐led outcome measure. Epilepsia Open 8:4, pages 1608-1615.
Crossref
Crossref
Mahd Nishtar, Remington Mark, Dale J Langford, Michael P McDermott, John D Markman, Scott R Evans, Fallon O France, Meghan Park, Sonia Sharma, Dennis C Turk, Robert H Dworkin & Jennifer S Gewandter. (2023) Evaluating the balance of benefits and harms in chronic pain clinical trials: prioritizing individual participants over individual outcomes. Regional Anesthesia & Pain Medicine, pages rapm-2023-104809.
Crossref
Crossref
James M. Chamberlain, Jaideep Kapur, Robert S. Silbergleit, Jordan J. ElmEric S. Rosenthal, Thomas P. Bleck, Shlomo ShinnarShahriar ZetabchiScott R. Evans. (2023) Desirability of Outcome Ranking for Status Epilepticus. Neurology 101:16.
Crossref
Crossref
Scott R Evans, Robin Patel, Toshimitsu Hamasaki, Jessica Howard-Anderson, Tori Kinamon, Heather A King, Deborah Collyar, Heather R Cross, Henry F Chambers, Vance G FowlerJrJr, Helen W Boucher, Pranita Tamma, Robert Schooley, Ritu Banerjee, Maria Souli, Zoe Sund, Beth Evans, Grant Booth, Leslie Estes, Kerryl Greenwood-Quaintance, Krupa Mukesh Parmar, Scott Cunningham, Nyssa Schwager, Cathy Wickward, Holly Geres, Weixiao Dai, Yijie He, Sarah Doernberg, Michael Satlin, Nadine Rouphael, Gayani Tillekeratne, Keri Baum, Praneeta Raza, Lauren Komarow, Andrew Dodd, Deborah Hopkins, Yixuan Li, Ephraim Tsalik, Thomas Holland & Shanshan Zhang. (2023) The Future Ain’t What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations. Clinical Infectious Diseases 77:Supplement_4, pages S321-S330.
Crossref
Crossref
Grecio J. Sandoval, William A. Grobman, Scott R. Evans, Madeline M. Rice, Rebecca G. Clifton, Suneet P. Chauhan, Maged M. Costantine, Kelly S. Gibson, Monica Longo, Torri D. Metz, Emily S. Miller, Samuel Parry, Uma M. Reddy, Dwight J. Rouse, Hyagriv N. Simhan, John M. ThorpJr.Jr., Alan T.N. Tita & George R. Saade. (2023) Desirability of outcome ranking for obstetrical trials: illustration and application to the ARRIVE trial. American Journal of Obstetrics and Gynecology.
Crossref
Crossref
Sean W.X. Ong, Neta Petersiel, Mark R. Loewenthal, Nick Daneman, Steven Y.C. Tong & Joshua S. Davis. (2023) Unlocking the DOOR—how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials. Clinical Microbiology and Infection 29:8, pages 1024-1030.
Crossref
Crossref
Leonardo Kapural, Nagy A Mekhail, Shrif Costandi, Christopher Gilmore, Jason E Pope, Sean Li, Corey W Hunter, Lawrence Poree, Peter S Staats, Rod S Taylor, Sam Eldabe, Jan Willem Kallewaard, Simon Thomson, Erika A Petersen, Dawood Sayed, Timothy R Deer, Ajay Antony, Ryan Budwany, Angela Leitner, Nicole Soliday, Rui V Duarte & Robert M Levy. (2023) Durable multimodal and holistic response for physiologic closed-loop spinal cord stimulation supported by objective evidence from the EVOKE double-blind randomized controlled trial. Regional Anesthesia & Pain Medicine, pages rapm-2023-104639.
Crossref
Crossref
R Ross MacLean, Eugenia Buta, Diana M Higgins, Mary A Driscoll, Sara N Edmond, Kathryn M LaChappelle, Brett Ankawi, Sarah L Krein, John D Piette & Alicia A Heapy. (2023) Using Daily Ratings to Examine Treatment Dose and Response in Cognitive Behavioral Therapy for Chronic Pain: A Secondary Analysis of the Co-Operative Pain Education and Self-Management Clinical Trial. Pain Medicine 24:7, pages 846-854.
Crossref
Crossref
Hannah Johns, Bruce Campbell, Guillaume Turc & Leonid Churilov. (2023) Power Analysis for Ordinal Analyses of the Modified Rankin Scale and an Online and Downloadable Tool for Practical Use. Stroke 54:7, pages 1750-1760.
Crossref
Crossref
Romney M. Humphries, Linda Miller, Barbara Zimmer, Erika Matuschek & Janet A. Hindler. (2023) Contemporary Considerations for Establishing Reference Methods for Antibacterial Susceptibility Testing. Journal of Clinical Microbiology 61:6.
Crossref
Crossref
Pranita D. Tamma & Sara E. Cosgrove. (2023) Which trial do we need? Early oral antibiotic therapy for the treatment of gram-negative bloodstream infections. Clinical Microbiology and Infection 29:6, pages 670-672.
Crossref
Crossref
Kanako Fuyama, Mitsunori Ogawa, Junki Mizusawa, Yukihide Kanemitsu, Shin Fujita, Takuya Kawahara, Kentaro Sakamaki & Koji Oba. (2023) Impact of correlations between prioritized outcomes on the net benefit and its estimate by generalized pairwise comparisons. Statistics in Medicine 42:10, pages 1606-1624.
Crossref
Crossref
Christina Yek, Alexander Lawandi, Scott R. Evans & Sameer S. Kadri. (2023) Which trial do we need? Optimal antibiotic duration for patients with sepsis. Clinical Microbiology and Infection.
Crossref
Crossref
Jessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, Deborah Collyar, Daniel Rubin, Sumathi Nambiar, Tori Kinamon, Carol Hill, Steven P Gelone, David Mariano, Takamichi Baba, Thomas L Holland, Sarah B Doernberg, Henry F Chambers, Vance G FowlerJrJr, Scott R Evans & Helen W Boucher. (2023) Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials. Clinical Infectious Diseases 76:3, pages e1157-e1165.
Crossref
Crossref
Scott R. Evans, Lijuan Zeng & Weixiao Dai. (2023) The Data and Safety Monitoring Board: The Toughest Job in Clinical Trials. NEJM Evidence 2:2.
Crossref
Crossref
Scott Evans. (2023) Response to Loewenthal et al. Clinical Infectious Diseases 76:1, pages 176-176.
Crossref
Crossref
Pranita D. Tamma, Maria Souli, Michael Billard, Joseph Campbell, Douglas Conrad, Damon W. Ellison, Beth Evans, Scott R. Evans, Kerryl E. Greenwood-Quaintance, Andrey A. Filippov, Holly S. Geres, Toshimitsu Hamasaki, Lauren Komarow, Mikeljon P. Nikolich, Thomas P. Lodise, Seema U. Nayak, Carmelle Norice-Tra, Robin Patel, David Pride, Janie Russell, Daria Van Tyne, Henry F. Chambers, Vance G. FowlerJr & Robert T. Schooley. (2022) Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial. Trials 23:1.
Crossref
Crossref
Nicholas A. Turner, Smitha Zaharoff, Heather King, Scott Evans, Toshimitsu Hamasaki, Thomas Lodise, Varduhi Ghazaryan, Tatiana Beresnev, Todd Riccobene, Rinal Patel, Sarah B. Doernberg, Urania Rappo, Vance G. FowlerJrJr & Thomas L. Holland. (2022) Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials 23:1.
Crossref
Crossref
Brenton P. Johns, David C. Dewar, Mark R. Loewenthal, Laurens A. Manning, Amit Atrey, Nipun Atri, David G. Campbell, Michael Dunbar, Christopher Kandel, Amir Khoshbin, Christopher W. Jones, Jaime Lora-Tamayo, Catherine McDougall, Dirk Jan F. Moojen, Jonathan Mulford, David L. Paterson, Trisha Peel, Michael Solomon, Simon W. Young & Joshua S. Davis. (2022) A desirability of outcome ranking (DOOR) for periprosthetic joint infection – a Delphi analysis. Journal of Bone and Joint Infection 7:6, pages 221-229.
Crossref
Crossref
Pranita D Tamma, Lauren Komarow, Lizhao Ge, Julia Garcia-Diaz, Erica S Herc, Yohei Doi, Cesar A Arias, Owen Albin, Elie Saade, Loren G Miller, Jesse T Jacob, Michael J Satlin, Martin Krsak, W Charles Huskins, Sorabh Dhar, Samuel A Shelburne, Carol Hill, Keri R Baum, Minal Bhojani, Kerryl E Greenwood-Quaintance, Suzannah M Schmidt-Malan, Robin Patel, Scott R Evans, Henry F Chambers, Vance G FowlerJrJr & David van Duin. (2022)
Clinical Impact of Ceftriaxone Resistance in
Escherichia coli
Bloodstream Infections: A Multicenter Prospective Cohort Study
. Open Forum Infectious Diseases 9:11.
Crossref
Crossref
Sarah B. Doernberg. (2022) Desirability of outcome ranking and quality life measurement for antimicrobial research in organ transplantation. Transplant Infectious Disease 24:5.
Crossref
Crossref
Jonathan S. Schildcrout, Frank E. HarrellJr.Jr., Patrick J. Heagerty, Sebastien Haneuse, Chiara Di Gravio, Shawn P. Garbett, Paul J. Rathouz & Bryan E. Shepherd. (2022) Model‐assisted analyses of longitudinal, ordinal outcomes with absorbing states. Statistics in Medicine 41:14, pages 2497-2512.
Crossref
Crossref
Bethea A. Kleykamp, Robert H. Dworkin, Dennis C. Turk, Zubin Bhagwagar, Penney Cowan, Christopher Eccleston, Susan S. Ellenberg, Scott R. Evans, John T. Farrar, Roy L. Freeman, Louis P. Garrison, Jennifer S. Gewandter, Veeraindar Goli, Smriti Iyengar, Alejandro R. Jadad, Mark P. Jensen, Roderick Junor, Nathaniel P. Katz, J. Patrick Kesslak, Ernest A. Kopecky, Dmitri Lissin, John D. Markman, Michael P. McDermott, Philip J. Mease, Alec B. O'Connor, Kushang V. Patel, Srinivasa N. Raja, Michael C. Rowbotham, Cristina Sampaio, Jasvinder A. Singh, Ilona Steigerwald, Vibeke Strand, Leslie A. Tive, Jeffrey Tobias, Ajay D. Wasan & Hilary D. Wilson. (2022) Benefit–risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain 163:6, pages 1006-1018.
Crossref
Crossref
Jessica Howard-Anderson, Weixiao Dai, Dafna Yahav, Toshimitsu Hamasaki, Adi Turjeman, Fidi Koppel, Erica Franceschini, Carol Hill, Zoë Sund, Henry F Chambers, Vance G FowlerJr.Jr., Helen W Boucher, Scott R Evans, Mical Paul, Thomas L Holland & Sarah B Doernberg. (2022) A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection. Open Forum Infectious Diseases 9:6.
Crossref
Crossref
Majid ChammasGerd Daniel PustGabrielle HattonClaudia PedrozaLillian KaoRishi RattanNicholas NamiasD. Dante Yeh Alouidor, Hing, Sharp, Dinnan, Kasotakis, Perez, Allmond, Long, Barth, Roman, Lawless, Cralley, Gelbard, Szczepanski, Eyer, Proulx, Wild, Young, Teicher, Lita, Morris, Juarez, Catalano, Turay, Cullinane, Roberts, Kaafarani, Eid, Ray—Zack, an, Portillo, Collom, Dodgion, Eddine, Tabrizi, Eid, Vasileiou, Evans, Vazquez, Saxe, Jacobson, Behrens, Schreiber, Joseph, Zeeshan, Nahmias, Sun, Crandall, Mull, Pasley, Meara, Gok, To, Rodriguez & Bradley. (2022) Outcomes of Restricted versus Liberal Post-Operative Antibiotic Use in Patients Undergoing Appendectomy: A DOOR/RADAR Post Hoc Analysis of the EAST Appendicitis MUSTANG Study. Surgical Infections 23:5, pages 489-494.
Crossref
Crossref
Simon P. Bach. (2022) Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR‐TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long‐course concurrent chemoradiotherapy versus short‐course radiotherapy organ preservation approaches. Colorectal Disease 24:5, pages 639-651.
Crossref
Crossref
David Hohenschurz-Schmidt, Bethea A. Kleykamp, Jerry Draper-Rodi, Jan Vollert, Jessica Chan, McKenzie Ferguson, Ewan McNicol, Jules Phalip, Scott R. Evans, Dennis C. Turk, Robert H. Dworkin & Andrew S.C. Rice. (2022) Pragmatic trials of pain therapies: a systematic review of methods. Pain 163:1, pages 21-46.
Crossref
Crossref
Marc Buyse & Julien Peron. 2022. Principles and Practice of Clinical Trials. Principles and Practice of Clinical Trials
1869
1893
.
Zachary R. McCaw, Lu Tian, Jiawei Wei, Brian Lee Claggett, Frank Bretz, Garrett Fitzmaurice & Lee‐Jen Wei. (2021) Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. Statistics in Medicine 40:28, pages 6235-6242.
Crossref
Crossref
David Lee, Björn Wettermark, Christine Y. Lu, Stephen B. Soumerai, Robert T. Chen, Sharon‐Lise T. Normand, Art Sedrakyan, Danica Marinac‐Dabic, Daniel B. Horton, Sonia Hernandez‐Diaz, Tamar Lasky, Krista F. Huybrechts, Claudia Manzo, Emil Cochino, Hanna M. Seidling, David W. Bates, Bennett Levitan, Rachael L. DiSantostefano & Scott Evans. 2021. Textbook of Pharmacoepidemiology. Textbook of Pharmacoepidemiology
387
463
.
Jennifer S. Gewandter, Shannon M. Smith, Robert H. Dworkin, Dennis C. Turk, Tong J. Gan, Ian Gilron, Sharon Hertz, Nathaniel P. Katz, John D. Markman, Srinivasa N. Raja, Michael C. Rowbotham, Brett R. Stacey, Eric C. Strain, Denham S. Ward, John T. Farrar, Kurt Kroenke, James P. Rathmell, Richard Rauck, Colville Brown, Penney Cowan, Robert R. Edwards, James C. Eisenach, McKenzie Ferguson, Roy Freeman, Roy Gray, Kathryn Giblin, Hanna Grol-Prokopczyk, Jennifer Haythornthwaite, Robert N. Jamison, Marc Martel, Ewan McNicol, Michael L. Oshinsky, Friedhelm Sandbrink, Joachim Scholz, Richard Scranton, Lee S. Simon, Deborah Steiner, Kenneth Verburg, Ajay D. Wasan & Kerry Wentworth. (2021) Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations. Pain 162:11, pages 2669-2681.
Crossref
Crossref
Belén Gutiérrez-Gutiérrez, Elena Pérez-Nadales, Salvador Pérez-Galera, Mario Fernández-Ruiz, Jordi Carratalà, Isabel Oriol, Elisa Cordero, José Antonio Lepe, Ban Hock Tan, Laura Corbella, Mical Paul, Alejandra M. Natera, Miruna D. David, Miguel Montejo, Ranganathan N. Iyer, Ligia Camera Pierrotti, Esperanza Merino, Seema Mehta Steinke, Meenakshi M. Rana, Patricia Muñoz, Alessandra Mularoni, Christian van Delden, Paolo Antonio Grossi, Elena María Seminari, Filiz Gunseren, Erika D. Lease, Emmanuel Roilides, Jesús Fortún, Hande Arslan, Julien Coussement, Zeliha Koçak Tufan, Benoit Pilmis, Marco Rizzi, Belén Loeches, Britt Marie Eriksson, Edson Abdala, Fabio Soldani, Warren Lowman, Wanessa Trindade Clemente, Marta Bodro, María Carmen Fariñas, Esra Kazak, Luis Martínez-Martínez, José María Aguado, Julián Torre-Cisneros, Álvaro Pascual & Jesús Rodríguez-Baño. (2021)
Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing
Enterobacterales
in Kidney Transplant Recipients
. Antimicrobial Agents and Chemotherapy 65:11.
Crossref
Crossref
Marc Buyse, Everardo D Saad, Julien Peron, Jean-Christophe Chiem, Mickaël De Backer, Eva Cantagallo & Oriana Ciani. (2021) The Net Benefit of a treatment should take the correlation between benefits and harms into account. Journal of Clinical Epidemiology 137, pages 148-158.
Crossref
Crossref
Kimberly C. Claeys, Teri L. Hopkins, Kathryn Schlaffer, Stephanie Hitchcock, Yunyun Jiang, Scott Evans, J. Kristie Johnson & Surbhi Leekha. (2021) Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT). Antimicrobial Agents and Chemotherapy 65:9.
Crossref
Crossref
Henry F Chambers, Scott R Evans, Robin Patel, Heather R Cross, Anthony D Harris, Yohei Doi, Helen W Boucher, David van Duin, Ephraim L Tsalik, Thomas L Holland, Melinda M Pettigrew, Pranita D Tamma, Kathryn R Hodges, Maria Souli & Vance G FowlerJr.Jr.. (2021) Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical Infectious Diseases 73:4, pages 730-739.
Crossref
Crossref
Grace Montepiedra, Soyeon Kim, Adriana Weinberg, Gerhard Theron, Timothy R Sterling, Sylvia M LaCourse, Sarah Bradford, Nahida Chakhtoura, Patrick Jean-Philippe, Scott Evans & Amita Gupta. (2021) Using a Composite Maternal–Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. Clinical Infectious Diseases 73:3, pages e587-e593.
Crossref
Crossref
Brigid M Wilson, Yunyun Jiang, Robin L P Jump, Roberto A Viau, Federico Perez, Robert A Bonomo & Scott R Evans. (2021) Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT): A Framework for Assessing Antibiotic Selection Strategies in the Presence of Drug Resistance. Clinical Infectious Diseases 73:2, pages 344-350.
Crossref
Crossref
Jennifer S. Gewandter, Michael P. McDermott, Scott Evans, Nathaniel P. Katz, John D. Markman, Lee S. Simon, Dennis C. Turk & Robert H. Dworkin. (2021) Composite outcomes for pain clinical trials: considerations for design and interpretation. Pain 162:7, pages 1899-1905.
Crossref
Crossref
Jill M. Ferdinands, Mark G. Thompson, Lenee Blanton, Sarah Spencer, Lauren Grant & Alicia M. Fry. (2021) Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine 39:28, pages 3678-3695.
Crossref
Crossref
Ashley Barlow, Emily L. Heil & Kimberly C. Claeys. (2021) Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection. Infectious Diseases and Therapy 10:1, pages 605-612.
Crossref
Crossref
Grace Montepiedra, Ritesh Ramchandani, Sachiko Miyahara & Soyeon Kim. (2020) A framework for considering the risk‐benefit trade‐off in designing noninferiority trials using composite outcome approaches. Statistics in Medicine 40:2, pages 327-348.
Crossref
Crossref
Robert H. Dworkin, Scott R. Evans, Omar Mbowe & Michael P. McDermott. (2021) Essential statistical principles of clinical trials of pain treatments. PAIN Reports 6:1, pages e863.
Crossref
Crossref
Marc Buyse & Julien Peron. 2020. Principles and Practice of Clinical Trials. Principles and Practice of Clinical Trials
1
25
.
Scott R Evans, Mikael Knutsson, Pierre Amarenco, Gregory W Albers, Philip M Bath, Hans Denison, Per Ladenvall, Jenny Jonasson, J Donald Easton, Kazuo Minematsu, Carlos A Molina, Yongjun Wang, KS Lawrence Wong & S Claiborne Johnston. (2020) Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. Clinical Trials 17:6, pages 617-626.
Crossref
Crossref
Yulia Sidi & Ofer Harel. (2020) Comprehensive Benefit–Risk Assessment of Noninferior Treatments Using Multicriteria Decision Analysis. Value in Health 23:12, pages 1622-1629.
Crossref
Crossref
Shannon M. Smith, Robert H. Dworkin, Dennis C. Turk, Michael P. McDermott, Christopher Eccleston, John T. Farrar, Michael C. Rowbotham, Zubin Bhagwagar, Laurie B. Burke, Penney Cowan, Susan S. Ellenberg, Scott R. Evans, Roy L. Freeman, Louis P. Garrison, Smriti Iyengar, Alejandro Jadad, Mark P. Jensen, Roderick Junor, Cornelia Kamp, Nathaniel P. Katz, James Patrick Kesslak, Ernest A. Kopecky, Dmitri Lissin, John D. Markman, Philip J. Mease, Alec B. O'Connor, Kushang V. Patel, Srinivasa N. Raja, Cristina Sampaio, David Schoenfeld, Jasvinder Singh, Ilona Steigerwald, Vibeke Strand, Leslie A. Tive, Jeffrey Tobias, Ajay D. Wasan & Hilary D. Wilson. (2020) Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain 161:11, pages 2446-2461.
Crossref
Crossref
Bryce E. Haac, Nathan N. O'Hara, Theodore T. Manson, Gerard P. Slobogean, Renan C. Castillo, Robert V. O'Toole & Deborah M. Stein. (2020) Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. PLOS ONE 15:8, pages e0235628.
Crossref
Crossref
Adam G Stewart, Patrick N A Harris, Mark Chatfield, Scott R Evans, David van Duin & David L Paterson. (2020) Modern Clinician-initiated Clinical Trials to Determine Optimal Therapy for Multidrug-resistant Gram-negative Infections. Clinical Infectious Diseases 71:2, pages 433-439.
Crossref
Crossref
Marc Buyse, Everardo D. Saad, Tomasz Burzykowski & Julien Péron. (2020) Assessing Treatment Benefit in Immuno-oncology. Statistics in Biosciences 12:2, pages 83-103.
Crossref
Crossref
Oliver N. Keene, Stephen Ruberg, Alexander Schacht, Mouna Akacha, Rachael Lawrance, Anna Berglind & David Wright. (2020) What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD. Pharmaceutical Statistics 19:4, pages 370-387.
Crossref
Crossref
Thomas P LodiseJr.Jr., Susan L Rosenkranz, Matthew Finnemeyer, Scott Evans, Matthew Sims, Marcus J Zervos, C Buddy Creech, Pratish C Patel, Michael Keefer, Paul Riska, Fernanda P Silveira, Marc Scheetz, Richard G Wunderink, Martin Rodriguez, John Schrank, Susan C Bleasdale, Sara Schultz, Michelle Barron, Ann Stapleton, Dannah Wray, Henry Chambers, Vance G FowlerJr.Jr. & Thomas L Holland. (2020) The Emperor’s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clinical Infectious Diseases 70:8, pages 1536-1545.
Crossref
Crossref
Edward W HookIIIIII, Lori Newman, George Drusano, Scott Evans, H Hunter Handsfield, Ann E Jerse, Fabian Y S Kong, Jeannette Y Lee, Stephanie N Taylor & Carolyn Deal. (2020) Development of New Antimicrobials for Urogenital Gonorrhea Therapy: Clinical Trial Design Considerations. Clinical Infectious Diseases 70:7, pages 1495-1500.
Crossref
Crossref
Ismail Jatoi & Mitchell H. Gail. (2020) The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology. JAMA Oncology 6:3, pages 420.
Crossref
Crossref
Dean Follmann, Michael P Fay, Toshimitsu Hamasaki & Scott Evans. (2019) Analysis of ordered composite endpoints. Statistics in Medicine 39:5, pages 602-616.
Crossref
Crossref
Sachiko Miyahara, Ritesh Ramchandani, Soyeon Kim, Scott R Evans, Amita Gupta, Susan Swindells, Richard E Chaisson & Grace Montepiedra. (2020) Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials. Clinical Infectious Diseases 70:4, pages 698-703.
Crossref
Crossref
Scott R. EvansRobert BigelowChristy Chuang-SteinSusan S. EllenbergPaul GalloWeili HeQi JiangFrank Rockhold. (2019) Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job. Annals of Internal Medicine 172:2, pages 119.
Crossref
Crossref
Bennett Levitan, Rachael L. DiSantostefano & Scott Evans. 2019. Pharmacoepidemiology. Pharmacoepidemiology
867
896
.
Daniele Roberto Giacobbe & Alessio Signori. (2019) Interpreting desirability of outcome ranking (DOOR) analyses in observational studies in infectious diseases: caution still needed. European Journal of Clinical Microbiology & Infectious Diseases 38:10, pages 1985-1986.
Crossref
Crossref
Matthew Reaney, Elizabeth Bush, Mary New, Jean Paty, Aude Roborel de Climens, Soren E. Skovlund, Linda Nelsen, Emuella Flood & Adam Gater. (2019) The Potential Role of Individual-Level Benefit-Risk Assessment in Treatment Decision Making: A DIA Study Endpoints Community Workstream. Therapeutic Innovation & Regulatory Science 53:5, pages 630-638.
Crossref
Crossref
Kan Li, Sheng Luo, Sammy Yuan & Shahrul Mt‐Isa. (2019) A Bayesian approach for individual‐level drug benefit‐risk assessment. Statistics in Medicine 38:16, pages 3040-3052.
Crossref
Crossref
Scott R Evans, Dean Follmann, Ying Liu, Thomas Holland, Sarah B Doernberg, Nadine Rouphael, Toshimitsu Hamasaki, Yunyun Jiang, Judith J Lok, Thuy Tien T Tran, Anthony D Harris, Vance G FowlerJrJr, Helen Boucher, Barry N Kreiswirth, Robert A Bonomo, David Van Duin, David L Paterson & Henry Chambers. (2019) Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS). Clinical Infectious Diseases 68:11, pages 1961-1967.
Crossref
Crossref
Sarah B Doernberg, Thuy Tien Tram Tran, Steven Y C Tong, Mical Paul, Dafna Yahav, Joshua S Davis, Leonard Leibovici, Helen W Boucher, G Ralph Corey, Sara E Cosgrove, Henry F Chambers, Vance G Fowler, Scott R Evans & Thomas L Holland. (2019) Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection. Clinical Infectious Diseases 68:10, pages 1691-1698.
Crossref
Crossref
Nicholas C. Henderson & Ravi Varadhan. (2018) Bayesian bivariate subgroup analysis for risk–benefit evaluation. Health Services and Outcomes Research Methodology 18:4, pages 244-264.
Crossref
Crossref
Scott Evans, Daniel B. Rubin, John H. Powers & Dean Follmann. (2018) Analysis Populations in Anti-Infective Clinical Trials: Whom to Analyze?. Statistical Communications in Infectious Diseases 10:1.
Crossref
Crossref
Jennifer S. GewandterJoanna BrellGuido CavalettiPatrick M. DoughertyScott EvansLynn HowieMichael P. McDermottAnn O'MaraA. Gordon SmithDaniela Dastros-PiteiLynn R. GauthierSimon HaroutounianMatthew JarpeNathaniel P. KatzCharles LoprinziPaul RichardsonEllen M. Lavoie-SmithPatrick Y. WenDennis C. TurkRobert H. DworkinRoy Freeman. (2018) Trial designs for chemotherapy-induced peripheral neuropathy prevention. Neurology 91:9, pages 403-413.
Crossref
Crossref
Pamela A Shaw. (2018) Use of composite outcomes to assess risk–benefit in clinical trials. Clinical Trials 15:4, pages 352-358.
Crossref
Crossref
Kay Dickersin, Dennis Dixon, Frederick Ferris, Judith Goldberg, Stephen Kimmel & John Lachin. (2018) University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session). Clinical Trials 15:4, pages 366-385.
Crossref
Crossref
David van Duin, Judith J Lok, Michelle Earley, Eric Cober, Sandra S Richter, Federico Perez, Robert A Salata, Robert C Kalayjian, Richard R Watkins, Yohei Doi, Keith S Kaye, Vance G FowlerJrJr, David L Paterson, Robert A Bonomo & Scott Evans. (2018) Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to
Carbapenem-Resistant Enterobacteriaceae. Clinical Infectious Diseases 66:2, pages 163-171.
Crossref
Crossref
Arthur R Celestin, Stephen R Odom, Konstantia Angelidou, Scott R Evans, Raul Coimbra, Christopher A Guidry, Joseph Cuschieri, Kaysie L Banton, Patrick J O’Neill, Reza Askari, Nicholas Namias, Therèse M Duane, Jeffrey A Claridge, E Patchen Dellinger, Robert A Sawyer & Charles H Cook. (2017) Novel Method Suggests Global Superiority of Short-Duration Antibiotics for Intra-abdominal Infections. Clinical Infectious Diseases 65:9, pages 1577-1579.
Crossref
Crossref
Scott R Evans & John Powers. (2017) Evaluating Anti-infective Drugs in the Resistant Pathogen Setting: Can We Use External Controls?. Statistical Communications in Infectious Diseases 9:1.
Crossref
Crossref